Personalis(NASDAQ) PSNL

Market Cap$1.82B

Since IPO (2019)-40%

5 Year-12%

1 Year+253%

1 Month+45%

Premium Feature

Moneyball Superscore

57/100

$17.44

+2.23%

+0.38Today

Personalis last closing stock price
Metric	Price	Date
Last close	USD 17.06	2026-08-24

Personalis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+22.82%	USD 13.89	2026-08-17
1 month	+44.82%	USD 11.78	2026-07-24
3 month	+90.83%	USD 8.94	2026-05-26
Year to date	+114.32%	USD 7.96	2025-12-31
1 year	+253.21%	USD 4.83	2025-08-22
3 year	+1,037.33%	USD 1.50	2023-08-25
5 year	-12.15%	USD 19.42	2021-08-25
Since inception	-40.12%	USD 28.49	2019-06-20

Personalis Financials at a Glance

Market Cap

$1.82B

Revenue (TTM)

$69.67M

Net Income (TTM)

-$107.18M

EPS (TTM)

-$1.09

P/E Ratio

-15.64

Dividend

$0.00

Beta (Volatility)

2.32 (High)

Dividend

$0.00

Beta (Volatility)

2.32 (High)

Price

$17.44

Volume

1,068,753.765

Open

$17.09

Price

$17.44

Volume

1,068,753.765

Open

$17.09

Previous Close

$17.06

Daily Range

$16.80 - $17.44

52-Week Range

$4.65 - $18.89

Estimated Earnings Date

Nov 3, 2026

Dividend

$0.00

Beta (Volatility)

2.32 (High)

Price

$17.44

Volume

1,068,753.765

Open

$17.09

Previous Close

$17.06

Daily Range

$16.80 - $17.44

52-Week Range

$4.65 - $18.89

Estimated Earnings Date

Nov 3, 2026

PSNL News

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Robert IzquierdoJun 4, 2026

If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now

Taylor CarmichaelJan 23, 2021

Personalis Turns to Liquid Biopsies for Growth. Will It Work?

Maxx ChatskoAug 14, 2020

Here's Why Personalis Fell as Much as 13.8% Today

Maxx ChatskoAug 12, 2020

2 Top Small-Cap Stocks to Buy in December

Maxx ChatskoDec 10, 2019

Page 1

PSNL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Personalis

Personalis helps doctors find and track cancer using genetic tests. These tests show how patients respond to their cancer treatments. Pharmaceutical companies also use this data to develop new medicines.

Tools for Tracking Cancer

Pharma Testing Services: Genetic sequencing and data analysis for clinical trials and research; generated $16.8 million in revenue in the second quarter of 2026.
Clinical Diagnostics: Tests that help physicians detect cancer recurrence and monitor treatment response; earned $2.5 million in revenue in the second quarter of 2026.
Population Sequencing: Large-scale research services provided for government projects like the U.S. Department of Veterans Affairs; accounted for $3.0 million in revenue in the second quarter of 2026.
NeXT Platform: Comprehensive tumor profiling tools that identify biomarkers to guide therapy from small tissue or plasma samples.

Recent Strategic Milestones

Agreed to a merger with Tempus in July 2026 to become a wholly owned subsidiary.
Secured Medicare reimbursement coverage for multiple cancer monitoring tests between Nov. 2025 and May 2026.
Established a commercial partnership with Tempus to market diagnostic tests through Nov. 25, 2029.
Completed a multiyear tumor analysis project with Natera in mid-2025.

High-Capacity Genetic Analysis

The company operates a high-capacity laboratory capable of sequencing over 350 trillion DNA bases every week. This infrastructure has allowed for the analysis of more than 605,000 human samples to date.

Quarterly Financial Performance

Total revenue reached $22.4 million in the second quarter of 2026, up 30% year over year.
Net loss was $31.7 million for the three-month period ended June 30, 2026.
Cash, cash equivalents, and short-term investments totaled $212.7 million as of June 30, 2026.
Market capitalization was $1.4 billion in the second quarter of 2026, up 143.3% year over year.

Bottom Line

Personalis has transitioned from a research-focused genomics firm to a clinical diagnostics provider with significant Medicare coverage. Its pending merger with Tempus represents a shift toward deeper integration within the precision medicine market.

AI Generated • Aug 5, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

260

CEO

Christopher M. Hall, MBA

Website

www.personalis.com

Headquarters

Fremont, CA 94555, US

PSNL Financials

Key Financial Metrics (TTM)

Gross Margin

12.69%

Operating Margin

-164.07%

Net Income Margin

-153.84%

Return on Equity

-46.47%

Return on Capital

-29.24%

Return on Assets

-34.34%

Earnings Yield

-6.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.82B

Shares Outstanding

106.80M

Volume

1.07M

Avg. Volume

4.19M

Financials (TTM)

Gross Profit

$8.84M

Operating Income

-$114.31M

EBITDA

-$97.22M

Operating Cash Flow

-$92.30M

Capital Expenditure

-$8.68M

Free Cash Flow

-$100.98M

Cash & ST Invst.

$212.66M

Total Debt

$38.00M

Personalis Performance Analysis

Personalis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 65,047,000	-23.9%
2023	2023-12-31	USD 73,481,000	13.0%
2024	2024-12-31	USD 84,614,000	15.2%
2025	2025-12-31	USD 69,648,000	-17.7%

Personalis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-15.7%
Q4	2025-12-31	19.7%
Q1	2026-03-31	-10.8%
Q2	2026-06-30	44.5%

Personalis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.48	66.8%
2023	2023-12-31	USD -2.25	-9.3%
2024	2024-12-31	USD -1.37	-39.0%
2025	2025-12-31	USD -0.91	-33.6%

Personalis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-4.3%
Q4	2025-12-31	-8.3%
Q1	2026-03-31	-11.5%
Q2	2026-06-30	-3.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$22.36M

+30.0%

Gross Profit

$4.74M

-0.3%

Gross Margin

21.21%

N/A

Market Cap

$1.82B

N/A

Market Cap/Employee

$7.01M

N/A

Employees

260

N/A

Net Income

-$31.68M

-58.0%

EBITDA

-$29.23M

-67.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$212.66M

+22.8%

Total Debt

$38.00M

-10.5%

Accounts Receivable

$15.10M

+51.7%

Inventory

$9.64M

+111.2%

Long Term Debt

$30.17M

-9.7%

Short Term Debt

$7.83M

-13.5%

Return on Assets

-34.34%

N/A

Return on Invested Capital

-43.01%

N/A

Free Cash Flow

-$29.55M

-123.5%

Operating Cash Flow

-$25.77M

-99.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TYRATyra Biosciences, Inc.

TYRATyra Biosciences, Inc.$26.73+2.45%

MRVIMaravai LifeSciences Holdings, Inc.

MRVIMaravai LifeSciences Holdings, Inc.$8.74+3.70%

BFLYButterfly Network, Inc.

BFLYButterfly Network, Inc.$9.27+3.52%

CDNACareDx, Inc

CDNACareDx, Inc$49.68+4.59%

CSTLCastle Biosciences, Inc.

CSTLCastle Biosciences, Inc.$34.39+2.73%

GERNGeron Corporation

GERNGeron Corporation$1.56+2.63%

FLGTFulgent Genetics, Inc.

FLGTFulgent Genetics, Inc.$19.73+1.42%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$210.64+0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.89+0.01%

INTCIntel

INTCIntel$88.29+0.01%

BMNRBitmine Immersion Technologies

BMNRBitmine Immersion Technologies$25.46+0.05%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.71+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.84+0.01%

Questions About PSNL

What is the current price of Personalis?

Personalis is trading at $17.39 per share.

What is the 52-week range for Personalis?

Over the past 52 weeks, Personalis has traded between $4.65 and $18.89.

How much debt does Personalis have?

As of the most recent reporting period, Personalis reported total debt of $38.00M.

How much cash does Personalis have on hand?

Personalis reported $93.97M in cash and cash equivalents in its most recent financial results.

What is Personalis’s dividend yield?

Personalis does not currently have a dividend yield.

Personalis(NASDAQ) PSNL

Personalis Financials at a Glance

PSNL News

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Personalis (PSNL) Q2 Revenue Falls 24%

Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

Why Personalis Stock Dropped Today

If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now

Personalis Turns to Liquid Biopsies for Growth. Will It Work?

Here's Why Personalis Fell as Much as 13.8% Today

2 Top Small-Cap Stocks to Buy in December

PSNL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Personalis

Tools for Tracking Cancer

Recent Strategic Milestones

High-Capacity Genetic Analysis

Quarterly Financial Performance

Bottom Line

PSNL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Personalis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PSNL

What is the current price of Personalis?

What is the 52-week range for Personalis?

How much debt does Personalis have?

How much cash does Personalis have on hand?

What is Personalis’s dividend yield?

Premium Investing Services